Treatment Information

Back

Breast Cancer treatment details. Chemotherapy.

Centre F. Baclesse, Caen, France.

Survival: monthsCountry:France
Toxiciy Grade:4City/State/Province:Caen
Treatments:ChemotherapyHospital:Centre F. Baclesse
Drugs:Journal:Link
Date:Nov 2005

Description:

Patients: This Phase II study involved 40 women with metastatic breast cancer. The median age was 61.5 years. Metastatic sites included viscera, lung, and liver. None of the patients had received primary chemotherapy treatment before the study.

Treatment: The treatment consisted of two chemotherapeutic agents: gemcitabine and paclitaxel.

Toxicity: Grade 3-4 toxicities included neutropenia, thrombocytopenia, leukopenia, anemia, and alopecia.

Results: The median overall survival was 25.7 months. Two patients had complete responses, twelve had partial responses, and fourteen achieved stable disease.

Support: Eli Lilly and Company helped the investigators with study design, analysis and interpretation of data; writing of the manuscript, and in the decision to submit the manuscript for publication. Furthermore, several authors are or were employees of Eli Lilly. Eli Lilly manufactures and/or markets gemcitabine.

Correspondence: Jean-Yves Genot, MD



Back